Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

Phase 1 Completed 68 enrolled Abramson Cancer Center at Penn Medicine American Heart Association · collab National Heart, Lung, and Blood Institute (NHLBI) · collab

RandomizedParallel-groupOpen-labelPrevention

Summary

Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with doxorubicin, trastuzumab, or the combination.

Timeline

Start: 2019-08-09
Primary completion: 2024-08-31
Completion: 2025-01-14

Publications

Jung W, Hubbard RA, Smith AM, Ko K, Huang A, Wang J, Isaacs JM, Zhang L, Liu PP, Chen Z, Shah PD, Mintzer D, Bhattacharya S, Knollman HM, Clark AS, Koropeckyj-Cox D, Messinger M, Wilcox NS, Xia C, Narayan V, Upshaw JN, Armenian SH, Ky B. Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial. Breast Cancer Res Treat. 2025 Jun;211(2):293-305. doi: 10.1007/s10549-025-07636-3. Epub 2025 Apr 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carvedilol	Other / unclassified	25 mg	—

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

Summary

Timeline

Publications

Drugs

Indications